Answers are grounded in this paper and cite their sources.
OBJECTIVE: To analyze the value of Down syndrome (DS) second-trimester maternal serum screening in large series of twin pregnancies. METHODS: Prospective study of second-trimester maternal serum markers [alpha fetoprotein (AFP) and free beta-human chorionic gonadotrophin (beta-hCG)] in 11,040 twin pregnancies, 27 of which were trisomy 21-affected. Comparison with 64,815 singleton pregnancies, of which 86 were trisomy 21-affected. Markers were expressed in multiple of median (MoM) corrected by a previously defined coefficient (2.1 for AFP and 2.07 or 2.16 for free beta-hCG, dichorionic or monochorionic, respectively). RESULTS: Trisomy 21 frequency was 1/649 for twins and 1/754 in singletons (NS). Mean detection rate was 63% (71% when both twins were affected and 60% when one was affected), versus 74.4% in singletons. False-positive rates were 10.8% in twins versus 10.3% in singletons (NS). No significant differences in MoM AFP and free beta-hCG values were noted between twins and singletons (0.92 and 0.78 for AFP and 1.54 and 2.68 for free beta-hCG, respectively). CONCLUSION: Our study demonstrates that second-trimester DS maternal serum marker screening can be performed in twin pregnancies.
No takes yet. Share an insight, caveat, or question.
Garchet‐Beaudron et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: